The average CSMS will be calculated based on daily symptom score and daily medication score recorded over the duration of the birch pollen season (BPS). CSMS is calculated by adding the Daily Medication Score (DMS) and Total Symptom Score (TSS) together, with scores ranging between 0 (none) and 38 (severe).

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season.

TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season

Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season

Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season

The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication taken as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The scale is 0 (minimum) to 20 (maximum)

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season

Number of participants with any Treatment Emergent Adverse Events (TEAEs) from participating in study

All participants in Safety Analysis Set (SAF) who received study drug and were recorded, if symptoms were displayed or not

Number of participants with any Serious Treatment Emergent Adverse Events (TEAEs) from participating in study

All participants in Safety Analysis Set (SAF) who received study drug and were recorded, if symptoms were displayed or not

Number of participants who showed change from baseline to the end of the study in Birch Skin Prick Test (SPT) Mean Wheal Diameter, in participants who received REGN5713-5714-5715 compared to placebo

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season

All randomized and treated participants who recorded and contributed to each timepoint (+/- 14 days)

All randomized and treated participants who recorded and contributed to each timepoint (+/- 14 days)

All randomized and treated participants who recorded and contributed to each timepoint (+/- 14 days)

Percentage of participants who developed antibodies to intervention provided during study

All randomized and treated participants who recorded and contributed to each timepoint (+/- 14 days)

Percentage of participants who developed antibodies to intervention provided during study

All randomized and treated participants who recorded and contributed to each timepoint (+/- 14 days)

Percentage of participants who developed antibodies to intervention provided during study

All randomized and treated participants who recorded and contributed to each timepoint (+/- 14 days)

"Well Days" are defined as days when rescue medication is not utilized and the Total symptom score (TSS) is ≤2/18

All randomized participants with at least 1 e-diary entry with symptoms or medication score recorded during the birch pollen season